TITLE: *FGFR4 p.Gly388Arg polymorphism in PBMCs of LAM Patients: A Potential Systemic Driver of Disease*

AUTHORS: Sinem Koc-Gunel[1]*, Amy L. Ryan [2], Melanie Winter [3], T.O.F. Wagner[4, 5]

AFFILIATIONS:

[1] Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany

[2] Department of Anatomy and Cell Biology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA

[3] Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt am Main, Germany.

[4] Frankfurt Reference Center for Rare Diseases (FRZSE), University Hospital Frankfurt, Goethe University Frankfurt, Germany

[5] European Reference Network for Respiratory Diseases (ERN-Lung), University Hospital Frankfurt, Goethe University Frankfurt, Germany

CORRESPOND:

*Sinem Koc-Günel (koc-guenel@med.uni-frankfurt.de)

Funding:

This study was supported by the German Research Foundation (DFG) (Grant No. KO5803/2-1 to SKG), the Federal Ministry for Research and Education Germany (BMBF) (Grant No. 01EO2102 to SKG) and departmental funds from the Department of Internal Medicine, Goethe University Frankfurt.

Abstract: LAM is a rare progressive lung diseases with neoplastic traits, which to date is known to be caused by mutations in the TSC2 gene leading to a hyperactivated mTOR pathway with uncontrolled cell growth. However, other mutations may contribute to disease progression. Here, we investigate the role of potential co-mutations, specifically the FGFR4 p.Gly388Arg polymorphism, previously identified as marker for aggressive cancer progression, as a potential co-driver in LAM. Peripheral blood mononuclear cells (PBMCs) from seven sporadic LAM patients were isolated and analyzed, using Next-Generation Sequencing (NGS) to identify tumorigenic mutations. The FGFR4 p.Gly388Arg variant was identified in four patients, with allelic frequencies ranging from 49% to 99%. The highest frequency was found in a patient with severe bullous lung disease, who eventually required lung transplantation. A moderate correlation (r = 0.55) between FGFR4 allelic frequency and lung function decline (FEV1%) suggests that this mutation may accelerate disease progression. Our findings indicate that FGFR4 mutations may play a role in the systemic nature of LAM, potentially exacerbating disease severity. Further research is required to explore FGFR4 as a biomarker and therapeutic target alongside mTOR inhibitors in LAM treatment strategies.

Lymphangioleiomyomatosis (LAM) is a rare, multisystemic and progressive disorder with neoplastic characteristics, primarily affecting the lungs (1). Although perceived as a benign lung disease, LAM is classified by the WHO as a perivascular epithelioid tumor (PEComa) due to neoplastic traits. LAM cells therefore exhibit invasive behavior, can cause extracellular matrix remodeling and can metastasize, similar to malignant tumors (2). Sporadic or inherited mutations in the TSC2 gene, and less frequently TSC1 gene, cause hyperactivation of the mTOR pathway, driving uncontrolled cell growth, though other co-driver mutations may also contribute to disease progression. Current treatment focuses on targeting LAM effector cells with TSC2 mutations using rapamycin, an mTOR inhibitor, which may slow lung function decline but may not reverse disease progression. As with many neoplasms, LAM may be driven by additional mutations beyond TSC2, particularly in genes involved in cell proliferation and signaling pathways. In this study, we identified a polymorphism in FGFR4, p.Gly388Arg, previously linked to aggressive cancers as a potential co-driver of disease progression.

This study included seven sporadic LAM patients monitored at a large academic hospital in Germany over 8 years. Written informed consent was obtained from all patients and the study was approved by the responsible Institutional Review Board and the Ethics Committee. Peripheral blood mononuclear cells (PBMCs) and clinical data, including lung function data, age, and treatment regimens (e.g., rapamycin) were collected. LAM diagnosis followed ATS/ERS guidelines, utilizing CT scans and, in some cases, serum VEGF-D levels or lung biopsies. To evaluate disease progression, pulmonary function tests (PFTs) were conducted over a period ranging from 1 to 8 years.

Next-Generation Sequencing (NGS) was performed for targeted mutation analysis of PBMCs using the Oncomine Comprehensive Assay v3 (Thermo Fisher) to identify tumorigenic mutations. This high-throughput NGS panel assesses 160 cancer-related gene mutations including key oncogenes, tumor suppressor genes, and genes associated with tumorigenesis pathways and is standardized for clinical settings. Therefore, genomic DNA was extracted, quantified, and subsequently sequenced, with data processed and analyzed using Ion

Reporter™ software, as previously described (3). The allelic frequency of each mutation was calculated, and results were validated against control samples. Lung function was evaluated using body plethysmography, measuring forced expiratory volume in one second (FEV1%) and FEV1/FVC ratio, among others. Utilizing advances in “liquid biopsy” technology from lung cancer research, we sought to assess whether LAM patients harbor systemic mutations in circulating cells that contribute to disease progression. To explore this, we performed targeted mutation analysis in isolated PBMCs from seven LAM patients.

The clinical and genetic characteristics of the patients included in the study are included in **Table 1.** Our analysis identified the FGFR4 p.Gly388Arg mutation in four of the seven patients at chromosome 5:176520243, with allelic frequencies of 49%, 49%, 99%, and 51%. The highest frequency (99%) was observed in patient STLAM1, who had severe bullous lung disease, characterized by large air-filled spaces (bullae) in the lungs, necessitating lung transplantation. Another patient, STLAM2, had a 49% FGFR4 mutation frequency along with a 56% TSC2 mutation frequency. Two additional patients were also identified as having FGFR4 mutations without accompanying TSC2 mutations. No FGFR4 mutations were detected in the other three patients, although they still exhibited cystic lung disease.

To investigate the relationship between FGFR4 mutations and disease progression, we analyzed the decline in lung function (FEV1%) across 52 pulmonary function tests conducted over time in these seven patients. We observed a moderate positive correlation ($r = 0.55$) between FGFR4 allelic frequency and the decline in FEV1%, suggesting a potential role of FGFR4 in accelerating lung function deterioration. Although not statistically significant, this highlights the need for further investigation in larger studies. **Figure 1** illustrates the changes in FEV1% over time for each individual patient.

Our study is the first to identify genetic alterations in PBMCs from LAM patients, indicating systemic involvement in the disease and reinforcing its neoplastic characteristics. While TSC2 mutations are the primary drivers of LAM, we highlight FGFR4 mutations, particularly the

p.Gly388Arg polymorphism, as potential co-drivers. The single nucleotide variant (SNV) causes a substitution of glycine with arginine at codon 388 in the FGFR4 receptor (4). This has been shown to alter the FGFR receptor domain and activate MAP kinase pathways previously, resulting in increased cell proliferation, survival, and tumorigenesis (5, 6). Previous systematic reviews have linked this polymorphism to poor cancer outcomes (7), suggesting it may exacerbate LAM progression. The FGFR4 p.Gly388Arg variant is found in approximately 33% of the global population according to a large study analyzing 16,179 controls. However, our analysis revealed a higher frequency of 56% in LAM patients, indicating a potential role in disease pathology (4). Further, this mutation has been linked to increased cell motility and metastasis in several cancers (7–9), and its presence in LAM-PBMCs, including T-lymphocytes, B-lymphocytes and natural killer (NK) cells, suggests a possible role in immune dysregulation. Thus, FGFR4 mutations in immune cells may amplify pro-fibrotic processes or contribute to unchecked proliferation of LAM cells. Notably, the high allelic frequency of the TSC2 mutation in PBMCs suggests a potential germline origin. However, patient STLAM2 showed no typical clinical features of tuberous sclerosis, indicating a more complex disease interplay.

Patient STLAM1, who exhibited a 99% allelic frequency of the FGFR4 p.Gly388Arg mutation, experienced severe disease progression. In contrast, STLAM7, who lacked the mutation and was observed over a similar timeframe, had a milder clinical course. This difference in outcomes underlines the potential role of FGFR4 p.Gly388Arg in disease progression and accelerated lung function decline in LAM patients. Furthermore, potential downstream pathways such as STAT, MAPK/ERK, and PI3K/AKT, which cross-talk with mTOR signaling (5, 6, 10), may be enhanced through the FGFR4 p.Gly388Arg polymorphism and thereby increase cell growth and survival.

In conclusion, targeting FGFR4 simultaneously with mTOR could present new therapeutic strategies for LAM patients, particularly those carrying FGFR4 mutations. Larger studies are

needed to confirm these findings and clarify the role of FGFR4 p.Gly388Arg in disease progression and treatment response.

References

1. Gupta N, Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR, *et al*. Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. *Am J Respir Crit Care Med* 2017;196:1337–1348.
2. Krymskaya VP, McCormack FX. Lymphangioleiomyomatosis: A Monogenic Model of Malignancy. *Annu Rev Med* 2017;68:69–83.
3. Ebner S, Winkelmann R, Martin S, Köllermann J, Wild PJ, Demes M. Sequencing of *BRCA1/2* -alterations using NGS-based technology: annotation as a challenge. *Oncotarget* 2022;13:464–475.
4. Peng T, Sun Y, Lv Z, Zhang Z, Su Q, Wu H, *et al*. Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer. *Sci Rep* 2021;11:1373.
5. Chou C-H, Hsieh M-J, Chuang C-Y, Lin J-T, Yeh C-M, Tseng P-Y, *et al*. Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility. *Oncotarget* 2017;8:96225–96238.
6. Quintanal-Villalonga Á, Ojeda-Márquez L, Marrugal Á, Yagüe P, Ponce-Aix S, Salinas A, *et al*. The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. *Sci Rep* 2018;8:2394.
7. Kim JH, Jeong SY, Jang HJ, Park ST, Kim HS. FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis. *Front Oncol* 2021;11:.
8. Xu W, Li Y, Wang X, Chen B, Wang Y, Liu S, *et al*. FGFR4 transmembrane domain polymorphism and cancer risk: A meta-analysis including 8555 subjects. *Eur J Cancer* 2010;46:3332–3338.
9. Xiong S-W, Ma J, Feng F, Fu W, Shu S-R, Ma T, *et al*. Functional *FGFR4* Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis. *Oncotarget* 2017;8:25300–25309.
10. Ulaganathan VK, Sperl B, Rapp UR, Ullrich A. Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site. *Nature* 2015;528:570–574.

Table 1: Clinical and Genetic Characteristics of LAM Patients.

Patient ID	STLAM1	STLAM2	STLAM3	STLAM4	STLAM5	STLAM6	STLAM7
Age Range	50-55	56-60	56-60	65-70	50-55	56-60	65-70
Gender	Female	Female	Female	Female	Female	Female	Female
LAM Type	Sporadic	Sporadic	Sporadic	Sporadic	Sporadic	Sporadic	Sporadic
FGFR4 Mutation	Yes	Yes	Yes	No	No	Yes	No
FGFR4 Allelic Frequency (%)	99	49	51	N/A	N/A	49	N/A
Mutation chromosome locus	chr5:176520243	chr5:176520243	chr5:176520243	N/A	N/A	chr5:176520243	N/A
Mutation type	SNV	SNV	SNV			SNV	
Mutation coverage	1989, 1992, 1959, 1995	1989, 1992, 1959, 1995	1989, 1992, 1959, 1995			1989, 1992, 1959, 1995	
TSC2 Mutation	No	Yes	No	No	Yes	No	No
TSC2 Allelic Frequency (%)	N/A	56	N/A	N/A	N/A	N/A	N/A
Mutation chromosome locus	N/A	chr16:2138268	N/A	N/A	N/A	N/A	N/A
Mutation type	N/A	INDEL	N/A	N/A	N/A	N/A	N/A
Mutation coverage	N/A	1993	N/A	N/A	N/A	N/A	N/A
Treatment	Sirolimus	Sirolimus	None	None	Sirolimus	Sirolimus	None

Angiomyolipoma (AML); History of (Hx); Long term oxygen therapy (LTOT); Single nucleotide variant (SNV).

Figure 1: FEV1 (%) over time and FGFR4 mutation status for LAM patients. FEV1 (%) over time in LAM patients, each symbol represents an individual patient. The figure shows a longitudinal assessment of lung function, highlighting variations in decline rates across patients with (red) and without FGFR4 (black) mutations.


140
120
100
80
60
40
20
FEV1%
0
1
2
3
4
5
6
7
8
Time (years)
Mutation
No Mutation
STLAM1
STLAM2
STLAM3
STLAM4
STLAM5
STLAM6
STLAM7